Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol

Abstract

AbstractCutaneous angiosarcoma (CAS) is an endothelial cell‐derived, highly aggressive type of vascular tumour. Although chemoradiotherapy with paclitaxel (PTX) is recognized as a first‐line therapy for CAS, second‐line therapy for CAS remains controversial, and there is no standard therapy for taxane‐resistant CAS. Plasminogen activator inhibitor‐1 (PAI‐1) is associated with poor clinical outcomes, and elevated levels of PAI‐1 in both tissue and serum are correlated with poor response to therapy in various cancers, including skin cancers. Since PAI‐1 protects endothelial cells from Fas ligand‐mediated apoptosis, PAI‐1 inhibition might induce apoptosis of endothelial cell‐derived tumours such as CAS. This is a single‐arm, open‐label, multi‐institutional, Phase 2 clinical trial to assess the efficacy and safety of PTX in combination with TM5614 (PAI‐1 inhibitor) in patients with PTX‐resistant CAS. PTX will be administered for 28 weeks, with oral administration of TM5614. The primary endpoint of this study will be the overall response rate (ORR) at 28 weeks after starting treatment (central image evaluation). The secondary endpoint will include the ORR at 28 weeks after starting treatment (investigator evaluation), ORR at 8 weeks and 16 weeks after initiation of treatment (central and investigator evaluation), progression‐free survival, overall survival, disease control rate and safety profiles. Assuming the null hypothesis of a response rate of 13.6% and an alternative hypothesis of 45%, a minimum of 15 patients are required to achieve a two‐sided, Type I error of 5% and power of 70% based on the exact binomial distribution. Data quality control will be conducted by a combination of centralized (remote) and on‐site monitoring. This study will contribute to the development of novel combination therapy for PTX‐resistant CAS patients, which remains an unmet clinical need.